Verapamil Dosing for Fascicular VT
For hemodynamically stable adults with fascicular (verapamil-sensitive) ventricular tachycardia, administer verapamil 5-10 mg (0.075-0.15 mg/kg) IV as a slow bolus over at least 2 minutes under continuous ECG and blood pressure monitoring, with a repeat dose of 10 mg (0.15 mg/kg) after 30 minutes if the initial response is inadequate. 1
Initial IV Dosing Protocol
The FDA-approved dosing for verapamil IV provides the foundation for acute treatment 1:
- Initial dose: 5-10 mg (0.075-0.15 mg/kg) IV bolus over at least 2 minutes
- Repeat dose: 10 mg (0.15 mg/kg) IV 30 minutes after first dose if inadequate response
- Administration: Must be given as slow IV push under continuous ECG and blood pressure monitoring
- Older patients: Administer over at least 3 minutes to minimize adverse effects
Why Verapamil Works for Fascicular VT
Fascicular VT involves reentry through the left ventricular Purkinje system (typically the left posterior fascicle) with a verapamil-sensitive slow conduction zone 2. This arrhythmia characteristically presents with:
- Right bundle branch block morphology with superior axis (most common)
- Relatively narrow QRS duration (0.13-0.16 seconds)
- Occurs predominantly in young patients without structural heart disease 3, 4
Verapamil terminates fascicular VT by blocking the calcium channel-mediated slow conduction zone, causing gradual slowing of the tachycardia (cycle length increases) followed by termination in approximately 85-100% of cases 3, 5.
Critical Safety Considerations
Absolute Requirements Before Administration:
- Confirm hemodynamic stability - systolic BP >80 mmHg, no altered mentation
- Verify the diagnosis - fascicular VT has distinct ECG features that differentiate it from other VTs
- Rule out contraindications:
Common Pitfall to Avoid:
Do NOT give verapamil for typical ischemic VT or polymorphic VT - this can cause profound hypotension, shock, or ventricular fibrillation 6, 7. The 2010 and 2025 AHA ACLS guidelines explicitly warn that verapamil should only be given to patients with narrow-complex tachycardias and avoided in rhythms consistent with VT 6, 7. However, fascicular VT is the specific exception because of its unique Purkinje-based mechanism 2.
Expected Response Pattern
Unlike adenosine (which has no effect on fascicular VT 3), verapamil produces:
- Gradual slowing of tachycardia rate before termination 3
- Stuttering termination rather than abrupt cessation
- Termination typically occurs within minutes of administration 5
If VT does not respond to verapamil, reconsider the diagnosis - true fascicular VT is highly verapamil-sensitive 3, 5, 4.
Ongoing Management After Acute Conversion
Following successful acute termination, chronic oral verapamil therapy is the drug of choice 2, 4:
- Oral dosing: 120 mg three times daily (240-320 mg/day total) 8, 5
- Efficacy: Prevents VT recurrence in 56-74% of patients 8
- Alternative: Catheter ablation is highly effective (>90% acute success) and potentially curative 2
Monitoring During Administration
Continuous monitoring is mandatory 1:
- ECG monitoring: Watch for AV block, bradycardia, or asystole
- Blood pressure: Hypotension is common; have vasopressors available
- Duration: Monitor for at least 30 minutes after administration
If Adverse Reactions Occur:
- Hypotension: IV fluids, calcium chloride (10% solution, 10-20 mL IV), vasopressors if needed
- Bradycardia/AV block: Atropine, temporary pacing if severe
- Asystole: Usually brief (<few seconds) with spontaneous recovery; if not, initiate ACLS 1